Form 4: Director Richard Lindstrom Receives Ocular Therapeutix Grant

Director Richard L. Lindstrom, M.D. was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.

Summary

• Director Richard L. Lindstrom, M.D. received an equity grant on June 10, 2026.
• The grant includes 14,000 restricted stock units (RSUs) and 44,000 stock options.
• The stock options have an exercise price of $8.74 per share.
• Both the RSUs and options vest 100% on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Continued service requirement for vesting creates dependency on the director's ongoing tenure.
• Market volatility could impact the value of the granted options and RSUs.

Future Outlook

The equity grants are subject to continued service on the board of directors, with full vesting expected by the first anniversary of the grant or the next annual meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with company performance milestones.

Comparison to Industry Standards

• The use of annual equity grants for board members is consistent with standard compensation practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice to ensure board continuity.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity instruments.

Next Steps

• Vesting of RSUs and options on the first anniversary of the grant or the next annual meeting of stockholders.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Transaction, Equity Grant, Director Compensation